Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A

Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A

SSZSE:301520
51.41
CNY
-2.11
(-3.94%)
0.08EPS
1,695.70P/E
6.62BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A carries a market capitalization of 6.62B, placing it among publicly traded companies globally. Its enterprise value stands at 5.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.62B
Enterprise Value5.72B

Share Statistics

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A has 93.17M shares outstanding.

Shares Outstanding93.17M

Valuation Ratios

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 1,695.70. The price-to-sales ratio is 26.53, and the price-to-book ratio stands at 4.42.

PE Ratio1,695.70
PS Ratio26.53
PB Ratio4.42
P/TBV Ratio5.24

Enterprise Valuation

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A trades at an EV/EBITDA multiple of 513.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 22.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 513.40 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.72B versus a market cap of 6.62B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales22.98
EV / EBITDA513.40
EV / EBIT513.40

Financial Position

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A maintains a current ratio of 8.65, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.13, indicating conservative leverage, while an interest coverage ratio of 153.35 demonstrates strong ability to service its debt obligations.

Current Ratio8.65
Quick Ratio6.72
Debt / Equity0.13
Debt / EBITDA0.18
Interest Coverage153.35

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 662,193.22 in revenue per employee across its workforce of 376.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee662,193.22
Employee Count376.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A recorded an income tax benefit of -2.30M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 5.05M, leaving 3.90M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-2.30M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A's stock has gained approximately 64.93% over the past 52 weeks. The 50-day moving average sits at 62.65, while the 200-day moving average is 44.26.

52-Week Price Change64.93%
50-Day Moving Average62.65
200-Day Moving Average44.26

Income Statement

CNY

Over the twelve months ended September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A generated 248.98M in revenue and converted that into 3.90M in net income, yielding earnings per share of 0.08. EBITDA reached 11.14M, while operating income came in at -5.80M.

Revenue248.98M
Gross Profit53.98M
Operating Income-5.80M
Pretax Income5.05M
Net Income3.90M
EBITDA11.14M
EBIT11.14M
Earnings Per Share (EPS)0.08

Balance Sheet

CNY

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A holds 936.21M in cash and equivalents against 1.96M in total debt, resulting in a net debt position of -169.27M. Total book value stands at 1.50B, with working capital of 1.07B providing operational flexibility.

Cash & Cash Equivalents936.21M
Total Debt1.96M
Net Debt-169.27M
Equity (Book Value)1.50B
Book Value Per Share16.07
Working Capital1.07B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-3.79M

Margins

Over the twelve months ended September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A posted a gross margin of 21.68, reflecting its pricing power and cost economics. The operating margin of -2.33 and net profit margin of 1.56 provide insight into operational efficiency.

Gross Margin21.68
Operating Margin-2.33
Pretax Margin2.03
Profit Margin1.56
EBITDA Margin4.48

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of 17.71 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.87, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A shareholders.

Dividend Per Share0.01
Payout Ratio17.71
Shareholder Yield0.87

Stock Splits

Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A's most recent stock split took place on June 12, 2026 with a 5:7 split ratio.

Last Split Date6/12/2026
Split Ratio5:7

Scores

As of September 30, 2026, Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A has an Altman Z-Score of 26.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score26.66